These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 25868706)

  • 21. Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy.
    Evens AM; Roy R; Sterrenberg D; Moll MZ; Chadburn A; Gordon LI
    Curr Oncol Rep; 2010 Nov; 12(6):383-94. PubMed ID: 20963522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation.
    Devizzi L; Guidetti A; Tarella C; Magni M; Matteucci P; Seregni E; Chiesa C; Bombardieri E; Di Nicola M; Carlo-Stella C; Gianni AM
    J Clin Oncol; 2008 Nov; 26(32):5175-82. PubMed ID: 18854569
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Post-transplant lymphoproliferative disorder in adult liver transplant recipients: a South American multicenter experience.
    Mendizabal M; Marciano S; dos Santos Schraiber L; Zapata R; Quiros R; Zanotelli ML; Rivas MM; Kusminsky G; Humeres R; Alves de Mattos A; Gadano A; Silva MO
    Clin Transplant; 2013; 27(4):E469-77. PubMed ID: 23758407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Post-transplant lymphoproliferative disorders in children: the role of chemotherapy in the era of rituximab.
    Gallego S; Llort A; Gros L; Sanchez de Toledo J; Bueno J; Moreno A; Nieto J; Sanchez de Toledo J
    Pediatr Transplant; 2010 Feb; 14(1):61-6. PubMed ID: 19344338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
    Muti G; Cantoni S; Oreste P; Klersy C; Gini G; Rossi V; D'Avanzo G; Comoli P; Baldanti F; Montillo M; Nosari A; Morra E;
    Haematologica; 2002 Jan; 87(1):67-77. PubMed ID: 11801467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Posttransplant lymphoproliferative disorders in lung transplant patients: the Cleveland Clinic experience.
    Ramalingam P; Rybicki L; Smith MD; Abrahams NA; Tubbs RR; Pettay J; Farver CF; Hsi ED
    Mod Pathol; 2002 Jun; 15(6):647-56. PubMed ID: 12065779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center.
    Leblond V; Sutton L; Dorent R; Davi F; Bitker MO; Gabarre J; Charlotte F; Ghoussoub JJ; Fourcade C; Fischer A
    J Clin Oncol; 1995 Apr; 13(4):961-8. PubMed ID: 7707124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.
    Evens AM; David KA; Helenowski I; Nelson B; Kaufman D; Kircher SM; Gimelfarb A; Hattersley E; Mauro LA; Jovanovic B; Chadburn A; Stiff P; Winter JN; Mehta J; Van Besien K; Gregory S; Gordon LI; Shammo JM; Smith SE; Smith SM
    J Clin Oncol; 2010 Feb; 28(6):1038-46. PubMed ID: 20085936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder.
    Hart M; Thakral B; Yohe S; Balfour HH; Singh C; Spears M; McKenna RW
    Am J Surg Pathol; 2014 Nov; 38(11):1522-9. PubMed ID: 25007145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rituximab therapy and reduction of immunosuppression to rescue graft function after renal posttransplantation lymphoproliferative disorder found by macrohematuria in a pancreas and kidney transplant recipient: a case report.
    Miyagi S; Sekiguchi S; Kawagishi N; Akamatsu Y; Satoh K; Takeda I; Fukushima D; Kobayashi Y; Tokodai K; Fujimori K; Satomi S
    Transplant Proc; 2011 Nov; 43(9):3299-301. PubMed ID: 22099782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab.
    Svoboda J; Kotloff R; Tsai DE
    Transpl Int; 2006 Apr; 19(4):259-69. PubMed ID: 16573540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Donor Monoclonal Gammopathy May Cause Lymphoproliferative Disorders in Solid Organ Transplant Recipients.
    Felldin M; Ekberg J; Polanska-Tamborek D; Hansson U; Sender M; Rizell M; Svanvik J; Mölne J
    Am J Transplant; 2016 Sep; 16(9):2676-83. PubMed ID: 27575725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radioimmunotherapy for NHL: experience of 90Y-ibritumomab tiuxetan in clinical practice.
    Hagenbeek A
    Leuk Lymphoma; 2003; 44 Suppl 4():S37-47. PubMed ID: 15154741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.
    Ansell SM; Ristow KM; Habermann TM; Wiseman GA; Witzig TE
    J Clin Oncol; 2002 Sep; 20(18):3885-90. PubMed ID: 12228209
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world Outcomes With Rituximab-based Therapy for Posttransplant Lymphoproliferative Disease Arising After Solid Organ Transplant.
    Burns DM; Clesham K; Hodgson YA; Fredrick L; Haughton J; Lannon M; Hussein H; Shin JS; Hollows RJ; Robinson L; Byrne C; McNamara C; Vydianath B; Lennard AL; Fields P; Johnson R; Wright J; Fox CP; Cwynarski K; Chaganti S
    Transplantation; 2020 Dec; 104(12):2582-2590. PubMed ID: 33104308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.
    Trappe RU; Dierickx D; Zimmermann H; Morschhauser F; Mollee P; Zaucha JM; Dreyling MH; Dührsen U; Reinke P; Verhoef G; Subklewe M; Hüttmann A; Tousseyn T; Salles G; Kliem V; Hauser IA; Tarella C; Van Den Neste E; Gheysens O; Anagnostopoulos I; Leblond V; Riess H; Choquet S
    J Clin Oncol; 2017 Feb; 35(5):536-543. PubMed ID: 27992268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial.
    Blaes AH; Peterson BA; Bartlett N; Dunn DL; Morrison VA
    Cancer; 2005 Oct; 104(8):1661-7. PubMed ID: 16149091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.
    Romero S; Montoro J; Guinot M; Almenar L; Andreu R; Balaguer A; Beneyto I; Espí J; Gómez-Codina J; Iacoboni G; Jarque I; López-Andújar R; Mayordomo-Aranda E; Montalar J; Pastor A; Pastor M; Piñana JL; Rojas-Ferrer N; Sánchez-Lázaro I; Sandoval J; Sanz G; Sanz MÁ; Solé A; Sanz J
    Leuk Lymphoma; 2019 Jan; 60(1):142-150. PubMed ID: 29966464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adapted treatment of Epstein-Barr virus infection to prevent posttransplant lymphoproliferative disorder after heart transplantation.
    Choquet S; Varnous S; Deback C; Golmard JL; Leblond V
    Am J Transplant; 2014 Apr; 14(4):857-66. PubMed ID: 24666832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
    Witzig TE; Flinn IW; Gordon LI; Emmanouilides C; Czuczman MS; Saleh MN; Cripe L; Wiseman G; Olejnik T; Multani PS; White CA
    J Clin Oncol; 2002 Aug; 20(15):3262-9. PubMed ID: 12149300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.